HC Wainwright & Co. Reiterates Buy on Plus Therapeutics, Maintains $3.5 Price Target
HC Wainwright & Co. analyst Sean Lee reiterates Plus Therapeutics (NASDAQ:PSTV) with a Buy and maintains $3.5 price target.
Earnings Scheduled For February 23, 2023
Companies Reporting Before The Bell
• ChipMOS TECHNOLOGIES (NASDAQ:IMOS) is likely to report earnings for its fourth quarter.
Plus Therapeutics Has Completed Of Enrollment In Cohort 2 Of The Respect-LM Phase 1/2a Dose Escalation Trial Of Rhenium (186Re) Obisbemeda For Leptomeningeal Metastases
The company said the next steps, following the Data and Safety Monitoring Board review anticipated next month, will be completing enrollment in Phase 1/Part A, followed by a meeting with the FDA to consider dose
Stocks That Hit 52-Week Lows On Tuesday
Tuesday's session saw 325 companies set new 52-week lows.
Why G Medical Innovations Shares Are Trading Lower By 35%; Here Are 25 Stocks Moving Premarket
Gainers
EUDA Health Holdings Limited (NASDAQ: EUDA) shares rose 88.1% to $8.40 in pre-market trading after merger completed with 8i Acquisition SPAC last week.
Plus Therapeutics Highlights Updates On Lead Program In Brain Cancer Indications
Plus Therapeutics Inc (NASDAQ:PSTV) presented data from two ongoing trials evaluating its lead investigational targeted radiotherapeutic, rhenium (186Re) obisbemeda, in recurrent…
Why Immunic Shares Jumped By Around 57%; Here Are 73 Biggest Movers From Yesterday
Gainers
Applied DNA Sciences, Inc. (NASDAQ: APDN) shares climbed 71% to close at $2.12 on Monday after the company announced it has received its largest single purchase order for LinearDNA™ valued above the mid-six-figures.
Why Applied DNA Sciences Shares Are Trading Higher By Around 65%, Here Are 54 Stocks Moving In Monday’s Mid-Day Session
Gainers
Applied DNA Sciences, Inc. (NASDAQ: APDN) shares jumped 64.5% to $2.03 after the company announced it has received its largest single purchase order for LinearDNA™ valued above the mid-six-figures.